Physician profile
Munawar Haider
NPI 1124018155
$14,064.17
in general payments reported to CMS, 2019-2025
61 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,722 · 2020: $1,437 · 2021: $1,991 · 2022: $1,827 · 2023: $2,378 · 2024: $2,410 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,929 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,928.74 |
| Education | $158.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,063.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $845.70 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $844.01 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $771.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $728.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $676.43 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $675.09 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $659.68 | 2021-2025 | |
| Amgen INC. | $621.02 | 2019-2025 | Evenity, Repatha, Prolia |
| Sunovion Pharmaceuticals INC. | $601.80 | 2019-2022 | |
| Abbvie INC. | $587.38 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $544.28 | 2019-2025 | |
| Abbott Laboratories | $506.43 | 2019-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.55 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $357.20 | 2021-2025 | Rexulti |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $336.66 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $320.75 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Sumitomo Pharma America, INC. | $283.77 | 2023-2024 | Gemtesa |
| Lundbeck LLC | $278.34 | 2023-2025 | Rexulti |
| Antares Pharma, INC. | $205.19 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Corcept Therapeutics | $202.46 | 2022-2024 | Korlym |
| Dexcom, INC. | $160.36 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $156.08 | 2019-2021 | |
| Eisai INC. | $154.68 | 2020-2025 | |
| Ucb, INC. | $144.11 | 2019-2025 | Briviact |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.67 | 2019-2023 | Relistor, Cycloset |
| Janssen Pharmaceuticals, INC | $130.81 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $124.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sk Life Science, INC. | $106.83 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $98.32 | 2022 | |
| Biogen, INC. | $85.73 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $84.97 | 2022-2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $84.87 | 2019-2021 | |
| Avvisto Therapeutics, LLC | $79.19 | 2025 | Cycloset |
| Shield Therapeutics INC | $76.33 | 2024 | |
| Nestle Healthcare Nutrition INC. | $72.15 | 2021-2023 | |
| Mylan Specialty L.P. | $71.08 | 2019-2020 | |
| Genentech USA, INC. | $67.46 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $62.45 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $57.76 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $55.74 | 2019-2023 | Nuplazid |
| Halozyme INC | $53.48 | 2023 | |
| Acorda Therapeutics, INC | $47.71 | 2019 | |
| Harmony Biosciences LLC | $45.70 | 2020 | |
| Evoke Pharma, INC. | $44.23 | 2020-2022 | |
| Globus Medical, INC. | $39.30 | 2025 | Senza |
| Xeris Pharmaceuticals, INC. | $33.03 | 2024-2025 | Gvoke Hypopen |
| Seqirus USA INC | $32.31 | 2022 | |
| Cmp Pharma, INC. | $30.87 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $29.26 | 2025 | Zoryve |
| Allergan, INC. | $29.15 | 2020 | |
| Axsome Therapeutics, INC. | $23.95 | 2025 | Sunosi |
| Fidia Pharma USA INC. | $22.18 | 2025 | Hymovis, Triluron |
| Ultragenyx Pharmaceutical INC. | $21.04 | 2022 | |
| Neurocrine Biosciences, INC. | $20.70 | 2025 | |
| Baxter Healthcare | $17.98 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Mannkind Corporation | $17.96 | 2019 | |
| Smith+Nephew, INC. | $17.12 | 2021 | |
| Linus Health, INC. | $13.58 | 2023 | |
| Cardiovascular Systems INC. | $12.98 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munawar Haider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.